Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
Early onset of type 2 diabetes and a high prevalence of co‐morbidities predispose the Asian population to a high risk for, and rapid progression of, diabetic kidney disease (DKD). Apart from renin‐angiotensin system inhibitors, sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have been shown to d...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839543/ https://www.ncbi.nlm.nih.gov/pubmed/33155749 http://dx.doi.org/10.1111/dom.14251 |
_version_ | 1783643405233946624 |
---|---|
author | Khoo, Chin Meng Deerochanawong, Chaicharn Chan, Siew Pheng Matawaran, Bien Sheu, Wayne Huey‐Herng Chan, Juliana Mithal, Ambrish Luk, Andrea Suastika, Ketut Yoon, Kun‐Ho Ji, Linong Man, Nguyen Huu Pollock, Carol |
author_facet | Khoo, Chin Meng Deerochanawong, Chaicharn Chan, Siew Pheng Matawaran, Bien Sheu, Wayne Huey‐Herng Chan, Juliana Mithal, Ambrish Luk, Andrea Suastika, Ketut Yoon, Kun‐Ho Ji, Linong Man, Nguyen Huu Pollock, Carol |
author_sort | Khoo, Chin Meng |
collection | PubMed |
description | Early onset of type 2 diabetes and a high prevalence of co‐morbidities predispose the Asian population to a high risk for, and rapid progression of, diabetic kidney disease (DKD). Apart from renin‐angiotensin system inhibitors, sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have been shown to delay renal disease progression in patients with DKD. In this review article, we consolidate the existing literature on SGLT‐2 inhibitor use in Asian patients with DKD to establish contemporary guidance for clinicians. We extensively reviewed recommendations from international and regional guidelines, data from studies on Asian patients with DKD, global trials (DAPA‐CKD, CREDENCE and DELIGHT) and cardiovascular outcomes trials. In patients with DKD, SGLT‐2 inhibitor therapy significantly reduced albuminuria and the risk of hard renal outcomes (defined as the onset of end‐stage kidney disease, substantial decline in renal function from baseline and renal death), cardiovascular outcomes and hospitalization for heart failure. In all the cardiovascular and renal outcomes trials, there was an initial decline in the estimated glomerular filtration rate (eGFR), which was followed by a slowing in the decline of renal function compared with that seen with placebo. Despite an attenuation in glucose‐lowering efficacy in patients with low eGFR, there were sustained reductions in body weight and blood pressure, and an increase in haematocrit. Based on the available evidence, we conclude that SGLT‐2 inhibitors represent an evidence‐based therapeutic option for delaying the progression of renal disease in Asian patients with DKD and preserving renal function in patients at high risk of kidney disease. |
format | Online Article Text |
id | pubmed-7839543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78395432021-02-01 Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations Khoo, Chin Meng Deerochanawong, Chaicharn Chan, Siew Pheng Matawaran, Bien Sheu, Wayne Huey‐Herng Chan, Juliana Mithal, Ambrish Luk, Andrea Suastika, Ketut Yoon, Kun‐Ho Ji, Linong Man, Nguyen Huu Pollock, Carol Diabetes Obes Metab Review Article Early onset of type 2 diabetes and a high prevalence of co‐morbidities predispose the Asian population to a high risk for, and rapid progression of, diabetic kidney disease (DKD). Apart from renin‐angiotensin system inhibitors, sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have been shown to delay renal disease progression in patients with DKD. In this review article, we consolidate the existing literature on SGLT‐2 inhibitor use in Asian patients with DKD to establish contemporary guidance for clinicians. We extensively reviewed recommendations from international and regional guidelines, data from studies on Asian patients with DKD, global trials (DAPA‐CKD, CREDENCE and DELIGHT) and cardiovascular outcomes trials. In patients with DKD, SGLT‐2 inhibitor therapy significantly reduced albuminuria and the risk of hard renal outcomes (defined as the onset of end‐stage kidney disease, substantial decline in renal function from baseline and renal death), cardiovascular outcomes and hospitalization for heart failure. In all the cardiovascular and renal outcomes trials, there was an initial decline in the estimated glomerular filtration rate (eGFR), which was followed by a slowing in the decline of renal function compared with that seen with placebo. Despite an attenuation in glucose‐lowering efficacy in patients with low eGFR, there were sustained reductions in body weight and blood pressure, and an increase in haematocrit. Based on the available evidence, we conclude that SGLT‐2 inhibitors represent an evidence‐based therapeutic option for delaying the progression of renal disease in Asian patients with DKD and preserving renal function in patients at high risk of kidney disease. Blackwell Publishing Ltd 2020-11-20 2021-02 /pmc/articles/PMC7839543/ /pubmed/33155749 http://dx.doi.org/10.1111/dom.14251 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Article Khoo, Chin Meng Deerochanawong, Chaicharn Chan, Siew Pheng Matawaran, Bien Sheu, Wayne Huey‐Herng Chan, Juliana Mithal, Ambrish Luk, Andrea Suastika, Ketut Yoon, Kun‐Ho Ji, Linong Man, Nguyen Huu Pollock, Carol Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title | Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title_full | Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title_fullStr | Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title_full_unstemmed | Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title_short | Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations |
title_sort | use of sodium‐glucose co‐transporter‐2 inhibitors in asian patients with type 2 diabetes and kidney disease: an asian perspective and expert recommendations |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839543/ https://www.ncbi.nlm.nih.gov/pubmed/33155749 http://dx.doi.org/10.1111/dom.14251 |
work_keys_str_mv | AT khoochinmeng useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT deerochanawongchaicharn useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT chansiewpheng useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT matawaranbien useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT sheuwaynehueyherng useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT chanjuliana useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT mithalambrish useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT lukandrea useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT suastikaketut useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT yoonkunho useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT jilinong useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT mannguyenhuu useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations AT pollockcarol useofsodiumglucosecotransporter2inhibitorsinasianpatientswithtype2diabetesandkidneydiseaseanasianperspectiveandexpertrecommendations |